Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-stroke Perturbation Training

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04855032
Recruitment Status : Recruiting
First Posted : April 22, 2021
Last Update Posted : February 14, 2022
Sponsor:
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Jesse Dean, PhD, Medical University of South Carolina

Brief Summary:
Following a stroke, many individuals have a high risk of falls, which can negatively influence quality of life. Unfortunately, current treatments have not effectively addressed this problem. This study investigates whether two methods of delivering mechanical perturbations during walking have the potential to improve post-stroke walking balance and reduce real-world fall incidence.

Condition or disease Intervention/treatment Phase
Stroke Behavioral: Reactive Perturbations Behavioral: Proactive Perturbations Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Proactive and Reactive Perturbation Training to Reduce Falls and Improve Gait Stability in People With Chronic Stroke
Actual Study Start Date : October 6, 2021
Estimated Primary Completion Date : June 1, 2026
Estimated Study Completion Date : June 1, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Falls

Arm Intervention/treatment
Experimental: Reactive Perturbations Behavioral: Reactive Perturbations
A novel device will be used to apply controlled mediolateral perturbations to participants' trunk as they walk on a treadmill, requiring reactive responses to avoid a loss of balance. All perturbations will have a duration of 200 ms, and will be applied immediately after onset of the swing phase with either the paretic or non-paretic leg. If in a given training session, a participant does not experience any losses of balance, the perturbation magnitude will be increased in the next training session. Perturbations will begin at 3% body weight (BW), and will progress in increments of 3% BW up to a maximum of 15% BW. The structure of the Reactive perturbation session will be identical to that used for Proactive perturbation training sessions, including overground trials, treadmill trials without perturbations, and Perturbed and Catch trials in which Perturbations are delivered.

Experimental: Proactive Perturbations Behavioral: Proactive Perturbations
A novel device will be used to perturb the relationship between pelvis motion and step width by applying mediolateral forces to participants' legs. Participants will first perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device. Participants will then perform a 3-minute treadmill walking trial at their self-selected speed, in which they again do not interact with the perturbation device. Participants will then perform a series of alternating 3-minute Perturbed and Catch trials, all at their self-selected speed. For the Perturbed trials, perturbations will be delivered in each step throughout the trial. For the Catch trials, perturbations will cease for the final minute of walking. A total of 5 Perturbed and 5 Catch trials will be performed. Finally, participants will perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device.




Primary Outcome Measures :
  1. Fall incidence [ Time Frame: 32 weeks (12-week period pre-intervention; 12-week period post-intervention) ]
    A fall will be defined as an event in which a participant loses their balance and comes to rest on the ground, floor, or lower level. Falls will be measured during the 12-week periods preceding and following the intervention, using 2-week calendars on postcards to be sent to the investigators.


Secondary Outcome Measures :
  1. Fear of falling [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    Participants will be asked if they have a fear of falling (yes/no).

  2. Functional Gait Assessment [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    A common clinical measure of gait balance

  3. Activities-specific Balance Confidence scale [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    A common clinical measure of balance self-efficacy

  4. Walking speed [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    Participants will be instructed to walk overground along a 10-meter path at the speed they would normally use around their house of the store. Speed will be measured for the middle 6-meters of the path.

  5. Foot placement stabilization strategy (mechanics) [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    We will calculate the partial correlation between the pelvis displacement at the start of each step, and step width at the end of the step, accounting for pelvis velocity.

  6. Foot placement stabilization strategy (gluteus medius activity) [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    We will calculate the partial correlation between the pelvis displacement at the start of each step, and the mean magnitude of gluteus medius activity during the first half of the swing phase, accounting for pelvis velocity.

  7. Center of pressure shift stabilization strategy (mechanics) [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    We will calculate the partial correlation between the pelvis velocity at the start of each step, and the magnitude of the change in mediolateral center of pressure location under the stance foot during the step, accounting for pelvis displacement.

  8. Center of pressure shift stabilization strategy (peroneus longus activity) [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    We will calculate the partial correlation between the pelvis velocity at the start of each step, and the mean magnitude of peroneus longus muscle activity during the single support stance phase of this step, accounting for pelvis displacement.

  9. Push-off stabilization strategy (mechanics) [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    We will calculate the partial correlation between the pelvis displacement at the start of each step, and the time integral of the total ground reaction force under the trail leg during the double support phase preceding this step, accounting for pelvis velocity.

  10. Push-off stabilization strategy (medial gastrocnemius activity) [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    We will calculate the partial correlation between the pelvis displacement at the start of each step, and the mean magnitude of medial gastrocnemius activity during the double support phase preceding this step, accounting for pelvis velocity.

  11. Largest rejected perturbation (trained perturbations) Largest rejected perturbation (trunk) [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    We will identify the largest mediolateral magnitude perturbation that participants can experience without a loss of balance.

  12. Largest rejected perturbation (untrained perturbations) Largest rejected perturbation (trunk) [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    We will identify the largest mediolateral magnitude perturbation that participants can experience without a loss of balance.

  13. Angular momentum modulation (trained perturbations) Largest rejected perturbation (trunk) [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    We will calculate the absolute difference in the range of frontal plane angular momentum during a step, relative to an unperturbed step. This will be calculated for the perturbed step and the subsequent recovery step.

  14. Angular momentum modulation (untrained perturbations) Largest rejected perturbation (trunk) [ Time Frame: 8 weeks (pre-intervention; post-intervention) ]
    We will calculate the absolute difference in the range of frontal plane angular momentum during a step, relative to an unperturbed step. This will be calculated for the perturbed step and the subsequent recovery step.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Experience of a stroke at least 6 months prior to participation
  • Self-reported experience of a fall in the previous year, and/or a fear of falling
  • Gait speed of at least 0.2 m/s
  • Ability to walk on a treadmill without a cane or walker
  • Provision of informed consent

Exclusion Criteria:

  • Evidence of cerebellar damage
  • Resting blood pressure higher than 220/110 mm Hg
  • History of unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living
  • Preexisting neurological disorders or dementia
  • Legal blindness or severe visual impairment
  • History of DVT or pulmonary embolism within 6 months
  • Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions
  • Orthopedic injuries or conditions (e.g. joint replacements) in the lower extremities with the potential to alter the gait pattern

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04855032


Contacts
Layout table for location contacts
Contact: Camden Jacobs 8437929013 jacobsca@musc.edu

Locations
Layout table for location information
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Camden Jacobs    843-792-9013    jacobsca@musc.edu   
Sponsors and Collaborators
Medical University of South Carolina
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
Layout table for investigator information
Principal Investigator: Jesse Dean Medical University of South Carolina
Layout table for additonal information
Responsible Party: Jesse Dean, PhD, Associate Professor, Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT04855032    
Other Study ID Numbers: 00101810
1R01HD103923-01 ( U.S. NIH Grant/Contract )
First Posted: April 22, 2021    Key Record Dates
Last Update Posted: February 14, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified participant data consisting of the clinical assessments and biomechanical walking data collected in this study will be shared through the IPCSR website.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: The data will be shared once the primary publication generated from this study has been published.
Access Criteria: No restrictions will be placed on the use of the data to be shared.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases